Mar 10, 2025
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
Mar 04, 2025
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Feb 25, 2025
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
Jan 22, 2025
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease
Jan 13, 2025
Rigel Provides Business Update and 2025 Outlook
Jan 09, 2025
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Jan 08, 2025
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 03, 2025
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dec 09, 2024
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
Nov 07, 2024
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 05, 2024
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
Oct 31, 2024
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
Oct 24, 2024
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
Sep 12, 2024
Rigel to Present at the 2024 Cantor Global Healthcare Conference
Aug 29, 2024
Rigel to Participate in Upcoming September Investor Conferences
Jul 12, 2024
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jun 24, 2024
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
Jun 14, 2024
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
May 07, 2024
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Apr 30, 2024
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update